ViiV Healthcare has announced that 20 abstracts from its portfolio of late-stage pipeline and authorised HIV treatments will be presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City, 21-24 July, in Mexico City, Mexico.
ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, continues its industry-leading commitment by delivering scientific advances that address the needs of the HIV community.
The data presented at IAS 2019 build upon the company’s innovative approach to research and development by investigating treatments that have the potential to reduce the number of medicines people living with HIV take during their lifetime, and provide a range of options that meet their diverse and evolving needs.
Highlights at IAS 2019 include the presentation of safety and efficacy data for the 2-drug regimen (2DR) of dolutegravir plus lamivudine in treatment-naïve and treatment-experienced patients; longer-term clinical trial data of investigational fostemsavir in heavily treatment-experienced patients; and pooled clinical trial data and patient-reported outcomes from the investigational long-acting, injectable 2DR of cabotegravir plus rilpivirine.
Dr John C. Pottage, Jr., Chief Scientific Officer and Medical Officer, ViiV Healthcare, said: “The depth and focus of our data at IAS 2019 is reflective of ViiV Healthcare’s patient-centred approach to innovation. We have made significant advances in the development of 2-drug treatment regimens and we are looking forward to presenting additional data regarding this new treatment paradigm.
“We are also looking forward to presenting long-term data for a new first in class therapy for people with few or no treatment options. With our pipeline of innovative medicines, we are aiming to make a difference in the lives of people living with HIV.”